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Chronic lymphocytic leukemia (CLL) cells express the receptor for Epstein-Barr virus (EBV) and can be infected in vitro.
Infected cells do not express the growth-promoting set of EBV-encoded genes and therefore they do not yield LCLs, in
most experiments. With exceptional clones, lines were obtained however. We describe a new line, HG3, established by
in vitro EBV-infection from an IGHV1–2 unmutated CLL patient clone. All cells expressed EBNA-2 and LMP-1, the
EBV-encoded genes pivotal for transformation. The karyotype, FISH cytogenetics and SNP-array profile of the line and
the patient’s ex vivo clone showed biallelic 13q14 deletions with genomic loss of DLEU7, miR15a/miR16–1, the two
micro-RNAs that are deleted in 50% of CLL cases. Further features of CLL cells were: expression of CD5/CD20/CD27/CD43
and release of IgM natural antibodies reacting with oxLDL-like epitopes on apoptotic cells (cf. stereotyped subset-1).
Comparison with two LCLs established from normal B cells showed 32 genes expressed at higher levels (. 2-fold).
Among these were LHX2 and LILRA. These genes may play a role in the development of the disease. LHX2 expression was
shown in self-renewing multipotent hematopoietic stem cells, and LILRA4 codes for a receptor for bone marrow stromal
cell antigen-2 that contributes to B cell development. Twenty-four genes were expressed at lower levels, among these
PARD3 that is essential for asymmetric cell division. These genes may contribute to establish precursors of CLL clones
by regulation of cellular phenotype in the hematopoietic compartment. Expression of CD5/CD20/CD27/CD43 and
spontaneous production of natural antibodies may identify the CLL cell as a self-renewing B1 lymphocyte.
Introduction
Chronic lymphocytic leukemia (CLL) develops as an expansion of
clonal CD5
+ B cell with mature phenotype. The proliferating
compartment is in the bone marrow and in the lymph nodes,
while the cells in the blood are arrested in G0/G1 phase. The gene
expression profile of CLL cells is similar to that of memory B
cells
1,2 and their phenotype is reminiscent of antigen experienced
B cells with CD23, CD27, IgM, IgD expression.
3 The precise
cell(s)-of-origin has not yet been established. Based on mouse B1
cell studies, a human B cell population (CD20
+, CD27
+, CD43
+,
CD5
+/CD5
-) characterized by spontaneous release of natural IgM
antibodies (Abs), efficient T cell stimulation and tonic intracel-
lular signaling was recently identified as human B1 cells.
4 It was
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pointed out that these cells share most properties with malignant
CLL cells at least of the poor prognosis type,
4 and may constitute
the normal counterpart of CLL. Evidence was also recently
presented that CLL pathogenesis involves self-renewing hemato-
poietic stem cells. From its multi-linear/polyclonal differentia-
tion products, mono/oligo-clonal cell population(s) with highly
biased IGHV-gene rearrangements arise,
5 most likely as a result
of (auto)antigen driven selection in a unique compartment (i.e.
pleural cavity or peritoneum) with special function for innate B
cells producing natural Abs.
CLL cells express the CD5 and CD6 scavenger receptors.
6,7
The majority of cases produce natural Abs.
8-10 These Abs are
produced both by restricted immunoglobulin heavy chain variable
(IGHV) gene “stereotyped” CLL cases (~30% of all CLL) and by
non-stereotyped cases. The Abs recognize epitopes on apoptotic
cells and on certain microbial structures.
8,11 CD5 expression and
this functional specificity defines the B1 “innate” B lymphocyte
subset.
8,9 While CD5
+ B cells represent a high proportion of the
B cells in cord blood (. 80%), primary follicles of fetal lymph
nodes, and spleen, they represent only 5–20% of the B cells in
adult blood and in adult lymphoid tissues.
Epstein-Barr virus (EBV) is not involved in the etiology of
CLL. The relationship of CLL B cells and EBV is however
unique. CLL cells separated from blood, express the EBV-
receptor CD21 and can be infected by the virus in vitro.
It is therefore remarkable that CLL cells generally do not
carry EBV genome. In the in vitro infected CLL cells, the
expression of EBV-encoded proteins is restricted and they
do not exhibit the complete growth program. The infected
cells do not express the EBV encoded cell membrane locali-
zed protein LMP1 that is essential for the transformation.
Consequently they do not yield lymphoblastoid lines.
12-14 In
rare cases, proliferating lines were obtained by infection of
the cells sometimes with simultaneous application of an
activating stimulus.
12,15 In these cases, the encoded EBV
genes required for transformation are expressed and the
derived LCLs resemble morphologically those derived
from normal B cells. Similarly to LCLs derived from cord
blood B lymphocytes, the CD5 marker initially present
disappeared during prolonged cultivation, in most cases.
16
We describe here the characteristics of an LCL estab-
lished by in vitro EBV infection of CLL cells. We emphasize
the authenticity of the cell line as demonstrated by the
karyotype with biallelic chromosome 13q14 deletions and
the unmutated IGHV genes being identical with the ex
vivo patient CLL cells. Its phenotype, CD5/CD19/ CD20/
CD27/CD43-positive, and its Ab production are features
of innate B1-like B cells. We attempted to trace character-
istics that may have been retained from the cell(s)-of-origin
of the CLL cell and therefore we compared expression of
a panel of genes with that of normal B cell derived LCLs.
We found higher expression of LHX2 a gene, which was
shown to promote self-renewal of a multi-potent hemato-
poietic progenitor cell. This gene may contribute to the
establishment of the malignancy and may have been
maintained in the LCL.
Results
Establishment of the lymphoblastoid cell line(s) by EBV
infection. The mononuclear cell population derived from the
patient’s blood was incubated with the B95–8 EBV virus for 1 h,
washed and cultured with or without CD40L-expressing L-cell
fibroblasts.
17 Lines were established from the freshly collected
samples and thereafter on four occasions from aliquots of the
sample that was stored frozen. The latency period for the
establishment of growing cell population was longer than it is
usually in experiments when normal B lymphocytes are infected
in vitro. For all parameters tested, the independently obtained
lines were identical. One of the cell lines designated HG3 was
selected and unless indicated these results are presented.
Cell surface phenotype with innate B1-like features. All estab-
lished cell lines strongly expressed CD5. Figure1A shows the
expression of a CD5, CD20, CD27, CD43 markers on the HG3
cells. The cell line showed a weak expression of the monocyte/
macrophage marker CD14, and expression of the activation
markers CD38 and CD70 (Fig.1A). The line was also positive
for CD19, CD21, CD31, CD69 (not shown). Upon prolonged
Figure1. (A) Human B1 phenotypic markers expressed on HG3. Indirect
immunofluorescence analysis with appropriate mAbs followed by FITC-of
Cy-ChromeTM-conjugated anti-mouse Ig. Ten thousands events were counted
in a FACScan flow cytometer. (B) Competition chemiluminescent ELISA for
oxLDL. MDA-LDL competition ELISA was performed for HG3 CLL IgM mAb
isolated from cell supernatant and purified by affinity chromatography.
Plates were coated with MDA-LDL, then IgM was allowed to react with
increasing amounts of soluble competitor MDA-LDL or native LDL (nLDL).
B/B0 indicates the ratio between bound (cpm) and bound (cpm) without
competitor.
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cultivation, CD5-expression was slightly decreased, whereas the
CD14,CD19,CD20,CD21,CD23,CD27,CD31,CD38,CD43,
CD69, CD70, IgM and l2light chain expression were retained.
IG gene rearrangements and antigen-binding specificity. The
IG gene sequence of the cells in a frozen stored ex vivo patient
sample and in the HG3 cell line were identical with unmutated
IGHV1–2 rearrangements (Fig.2). The unmutated IGLV2–14
light chain gene rearrangements were identical as well (not
shown). It did not belong to any known stereotyped subset.
18 The
HG3 cells spontaneously released IgM mAb that bound to
oxidized low density lipoprotein (oxLDL) epitopes of the
malonedialdehyde type (MDA-LDL), but not to native LDL
(Fig.1B). This specificity was previously shown for CLL Abs
belonging to the stereotyped subset-1.
8,11 However, ex vivo CLL
cells did not release IgM unless they were activated by CpG .
Karyotype, FISH, SNP-array and RQ-PCR analysis. The
karyotypes of the ex vivo cells and the cell line showed biallelic
13q14 deletions, 46,XY,del(13)(q14)x2 (Fig.3). It was confirmed
in fluorescence in situ hybridization (FISH) and single nucleo-
tide polymorphism (SNP) array analysis. The biallelic deletions
included genomic loss of DLEU7, miR15a and miR16–1(Fig.4).
Real-time quantitative polymerase chain reaction (RQ-PCR)
confirmed loss of miR15a expression, however, miR16–1 RQ-
PCR was positive. In addition, insertions were detected on
chromosomes 11 and 14 in the cell line (Fig.3A and B) but not
in the ex vivo CLL cells.
Gene expression profiles. In comparative analysis of the
expression of 21,632 genes in the HG3 line vs. two LCLs derived
from normal B cells, IARC-171 and LCL-3M (Table S1A and
S1B) 32 genes were found to be expressed relatively higher and
24 genes were expressed relatively lower. For a few selected genes
the results were validated by quantitative PCR.
Genes expressed with a 2-fold (or over) difference in the HG3
cells included LHX, and LILRA4. Among the relatively low
expressed genes were PARD3, FCRLA and TCL1. The LHX2
(LIM homeobox 2) gene was expressed 20-fold higher in HG3
compared with LCL-3M (Table 1). In three of four addi-
tional CLL-LCLs (232B4, I83-E95, CI, MEC1), high expression
of LHX2 was detected (Table 1). The LILRA4 [leukocyte
immunoglobulin-like receptor, subfamily A (with TM domain),
member 4] gene also showed higher expression (Fig.5). Reduced
expression was found for FCRLA (cytochrome p450, family 1,
subfamily B, polypeptide 1) (Fig.5 and Table 1), CYP1B1
(Fig.5), the polarity complex gene PARD3 [par-3 partitioning
defective 3 homolog (C. elegans)] (Table 1) and TCL1A.
Expression of EBV encoded proteins EBNA-2 and LMP-1 in
HG3. The EBV encoded nuclear antigen EBNA-2 and the latent
membrane protein LMP-1 were expressed in all cells as seen by
immunofluorescence. This characterizes the growth program
denoted as type III EBV expression. As in LCLs generated from
normal B lymphocyte population, the levels of both proteins
were variable and they were not related. Figure6 shows the
simultaneous staining with both antibodies. Similar results were
detected by single staining for each antigen (not shown).
Discussion
Despite recent advancements in the CLL field, the cell(s)-of-origin
and the transforming event(s) are largely unknown. The expres-
sion of CD5 on CLL cells is an obligatory marker for classifica-
tion of the disease. CD5 appears early in the differentiation of
T lymphocytes and it is abundantly expressed on the mature
T cells. In addition, CD5 can be detected in a subset of
B lymphocytes with frequencies varying in different develop-
mental stages, anatomical localization and function. The CD5
+
B cells, referred to as B1 cells in mice, are self-renewing and
produce natural Abs. A small fraction of human B cells with a
CD20
+CD27
+CD43
+CD70
- phenotype (partially overlapping
with CD5
+ B cells), showing natural IgM secretion and a capacity
to stimulate T cells, was recently detected in umbilical cord and
in adult peripheral blood.
4 These cell are candidates for the B1
subset in humans,
4 and may be one of the proposed CLL
precursor(s).
19 The CLL-derived permanent cell line described
in this study resembles these human B1 cells both with regard to
its surface marker profile and to its function as a natural Ab
secreting cell. An exception is CD70, which is expressed in HG3,
but low or absent in the putative human B1 population. This
is explained, however, by findings in previous reports showing
that ex vivo CLL cells are CD70-negative
4,20 or weakly positive,
21
whereas all LCLs are CD70-positive.
22 The B1 cell capacity to
stimulate T cells, which is one of the functional markers, appear
not to be shared by resting ex vivo blood CLL cells, whereas
activated CLL cells do stimulate.
23 The B1 function of tonic
intracellular signaling is found in CLL cells isolated from lymph
nodes, which display gene expression profiles that indicate BCR
activation.
24,25 However, in LCLs, the BCR signaling is hi-jacked/
blocked by the virally encoded protein LMP2A.
26 With these
notions, the HG3 line recapitulates a B1 cell.
The human CD5
+ B cells represent a minority in the adult B
cell population, while in the cord blood . 80% of the cells are
Figure2. Identical IGHV1–2 gene rearrangements in HG3 and the patient’s CLL cells.
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positive. Ab production of the CD5
+ B subset is “innate,” prompt
and T cell independent. It contributes, however, to the deve-
lopment of T cell-dependent, adaptive Ab response.
27 The
CD5
+ B subset is considered to play a role in the pathogenesis
of autoimmune diseases.
28 The production of ‘natural’ IgM Abs
by CLL clones suggests that they are derived from B cells with
Figure4. Zoom in picture of the homozygous 13q4 deletion. The array revealed that DLEU-7, miR16–1 and miR15a were deleted.
Figure3. SNP array analysis and karyotype reveal biallelic chromosome 13 deletions. (A and B) show results from SNP array analysis in HG3 cell line
and HG patient. Red marking show deletions and green marks show amplifications. (C and D) G-banding are showing identical biallelic deletions
of chromosome 13 in HG3 cell line and in HG patient’s leukemic clone.
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reactivity against self and neo-self epitopes and by that the
proliferation of cells may be induced by (auto)antigenic pressure.
One of the most frequent epitopes recognized by natural Abs
present on apoptotic cell membranes/blebs and on the surface
of multiple bacterial species is the oxLDL-like epitope.
8,11 This
was also recognized by the HG3 IgM Abs.
The expression of the CD5 marker in the context of the EBV-
induced transformation of B cells deserves closer investigation.
In contrast to normal B lymphocytes, EBV infected CLL cells
do not develop to LCLs.
17,29 The virally encoded protein
expression is restricted, the cells express EBNAs, but not LMP-
1 that is also required for transformation.
The HG3 cell line and other CLL derived LCLs initially
expressed CD5, but it diminished (in some cases) after prolonged
cultivation. In cord blood B cells CD5-expression disappeared
already 72 h after infection.
30 The HG lines are unique as they
maintained CD5 expression. The transformed cells that yielded
the HG3 cell line appeared with a delay in the in vitro infected
CLL cultures. This suggests that the phenotype of a few CLL
cells changed in the culture, including probably the appearance
of cellular factors, which were required for expression of the
transforming EBV genes. The recent report that CLL cells
share characteristics with spontaneous IgM secreting B1 cells
4
may explain why mature CD5
+ B cells that harbor IgM and
IgD secretory granulae, cannot be immortalized by EBV. We
previously showed that secretory differentiation in the LCLs
accompanied downregulation of EBNA,
31 and slowdown of
proliferation. 10–20% of the natural Ab producing CD5
+ B cells
have the secretory machinery, and this differentiated phenotype
may be incompatible with expression of the EBV transforming
genes. We suggest, based on the presence of early pro-B cell
markers in the HG3 cells, that these cells are less mature and
thus transformable by EBV. More mature lymphoblasts/plasma-
blasts cannot be transformed by EBV.
In comparing proliferating CLL cell with normal proliferat-
ing B cells it can be assumed that influences on the gene
expression arising from tissue culture microenvironment or
presence of EBV would be the same for all LCLs, whether
CLL-derived (HG3) or derived from normal B cells (LCL-3M
and IARC-171). Our gene profile comparison with conventional
Table1. LHX2, PARD3 and FCRLA mRNA levels in CLL-derived LCL lines
related to its expression in LCL-3M derived from normal B cells
Cell line Derivation LHX2
(fold higher
expression)
PARD3
(fold lower
expression
FCRLA
(fold lower
expression)
LCL-3M normal B cells (1) (1) (1)
HG3 CLL 19.7 3.8 6.0
CI (Corina I) CLL 30.9 - -
MEC1 CLL/PLL 30.0 - -
I83-E95 CLL 12.6 - -
232B4 CLL 0.9 - -
RQ-PCR analysis. The values represent means of triplicate measurement
obtained in 2 independent experiments. GAPDH was used as reference.
Figure5. Gene expression difference observed by RT-PCR. Comparison
between gene expression of LILRA4, FCRLA and CYP1B1 using RT-PCR in
the CLL-HG cell line and 2 LCL lines IARC-171 and LCL-3M derived from
normal B cells.
Figure6. Multicolor immunofluorescence for EBNA-2 and LMP-1. From left to right: DAPI staining (Vectashield) for nuclear DNA; EBNA-2 staining with
mouse anti-EBNA-2 mAb clone PE2, followed by goat anti-mouse IgG1-Alexa488; LMP-1 staining with anti-LMP-1 mAb clone S-12, followed by anti-mouse
IgG-Alexa594; Merged image of EBNA-2 and LMP-1.
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normal B cell derived LCLs showed elevated expression of some
genes involved in early B cell development, among these, the
higher expression of the LHX2, which was shown to promote
self-renewal of a multi-potent hematopoietic progenitor cell,
and LILRA4 may be of particular significance in view of the
recent findings of Kikushige et al.
5 showing that self-renewing
hematopoietic stem cells are the primary targets in pathogenesis
of human CLL.
LHX2 codes for a regulatory protein involved in the dif-
ferentiation of lymphoid multipotient progenitor cells with
self-renewal properties.
32,33 It is also expressed in chronic
myelogeneous leukemia (CML).
34 In embryonic mouse and rat
liver tissue, LHX2 was found to be expressed early during B
cell differentiation in a subepithelial lymphoid compartment.
Recent studies in CLL and in normal blood B cells
35 showed
that LHX2 was lower (or absent) in the CLL cells.
1,2,35 However,
our comparison of CLL-LCL and conventional LCLs showed
the opposite relationship. It is possible that the different results
are explained by the fact that we analyzed proliferating cells,
whereas blood CLL cells as analyzed previously by others,
represent resting G0/G1 cells. The LHX2 expressing embryonic
lymphoid cells may resemble a unique human CD5
+ B cell
population, detected in the marginal zone equivalent in tonsil
subepithelial areas.
36 These B cells were shown to produce Abs
to T-independent antigens (natural Abs), and it was charac-
terized by a memory B1-like profile with CD5
+CD20
+CD27
+
phenotype, thus resembling CLL B cells and the B1 cells.
The LILRA4 gene, also known as ILT7 (immunoglobulin-like
transcript 7) and CD85 g, is a member of a large family of
leukocyte-Ig-like receptors,
37 which is mostly expressed on plas-
macytoid dendritic cells. It was recently identified as receptor
for bone marrow stromal cell antigen-2 (BST2; CD317)
38 that
is important for pre-B cell development. Thus, the expression
of the gene in HG3 may reflect the developmental stage of the
CLL cell precursor. It was also found that a genetic variant of
LILRA4 (LILRA4 P27L) was associated with progression free
survival in a cohort of 977 CLL patients.
39
The majority (89%) of CLL cases express the macrophage
marker CD14,
40 also found in HG3, whereas in a panel of
37 conventional LCLs, all were negative for CD14.
41 CD14
functions as a receptor for LPS, as well as a receptor for apopto-
tic cells,
42 and it is a co-receptor for Toll-like receptors (TLR) 7
and 9, which are expressed in CLL cells.
43,44 Interestingly, soluble
CD14 derived from monocytes was recently shown to be a growth
factor for CLL.
45
Based on CLL mAb specificity with binding to epitopes on
apoptotic cells (oxLDL-like epitopes and non-muscle myosin)
8,46
and certain microbes, we assumed that the CLL precursor B cells
belong to a B1 cell subset endowed with specialized innate B cell
scavenging functions for prompt removal of apoptotic cells. In
addition, several reports describe co-receptors for apoptotic cells,
including CD36 (receptor for oxLDL-like epitopes) and CD31
that is involved in tethering apoptotic cells.
47 CD5 and CD6 are
scavenger receptors for certain microbes i.e., b-glycan of fungal
cell wall components.
48,49 For this function, CLL and CD5
+ cells
share many properties with macrophages. Whether the CLL cell
(s)-of-origin belong to a bipotential B-macrophage progenitor,
which has also been identified in bone marrow of adult mice,
50
requires further studies. CD31 was found to be relatively higher
expressed in HG3 cell line. One of the receptors for CD31 is
CD38, which is found on all proliferative i.e., Ki67-positive CLL
cells in the proliferative compartment of pseudofollicles.
51 CD31
have important functions for removal of apoptotic cell,
47 and the
CD31/CD38 interaction may induce self-renewal CLL prolifera-
tion. CD38 was also expressed on the HG3 cells.
One of the genes that were expressed at a low level comparing
HG3 vs. LCLs from normal B cells was PARD3, first identified
in C. elegans. It is essential for asymmetric cell division and
polarized growth. PARD3 is thought to be a master regulator
of apical-basal cell polarity, a process that has been indirectly
implicated in tumorigenesis. Loss of PARD3 leads to abnormal
cell contacts, and it was recently shown that disruption of polarity
complex genes (PARD3) is frequent in human cancers.
52 We
speculate that during the leukemogenesis of CLL, disrupted
PARD3 could lead to loss of cell-contacts in the normal
(subepithelial) compartment, inducing dissemination of the cells.
The karyotype of HG3 line and the patient’s CLL clone
showed biallelic 13q14 deletions, with genomic loss of DLEU7,
miR15a and miR16–1. These are two micro-RNAs that are
reduced in most CLL cases, with or without 13q14 deletion.
53
The complex regulation of miR15a/16–1 is not fully understood,
but they are suggested to be involved in regulating proliferation
and apoptosis.
54-56 They are expressed as a cluster within intron
4o fDLEU2 and are regulated by the DLEU2 promoter.
54
Thus, any genetic alteration of DLEU2 can also affect miR-15a/
16–1 expression. In our analysis of miR15a and miR16–1i n
HG3, we found that the two miRs were deleted, whereas this
genomic loss did not conform with the RQ-PCR that revealed
loss of mR15a and relatively high expression of miR16–1. The
reason for detecting miR-16–1 in RQ-PCR, although it is
deleted, is because miR-16–2 of the miR-15b/16–2 cluster
(chromosome 3) has exactly the same sequence (kindly pointed
out by Drs. C. Croce and U. Klein). This may indicate that
miR-15a is probably more important than miR-16 during CLL
leukemogenesis. It is important to note that the chromosome
13q14 deletion does not counteract the EBV induced trans-
formation event.
In summary, the LCL derived from an IgM IGHV unmutated
CLL case is authentic and maintained characteristics of the CLL
cell, such as CD5
+, CD20
+, CD27
+, CD43, natural IgM, l Ab
secretion with restricted target structure recognition. The biallelic
chromosome 13q14 deletion was identical in the patient and
cell line, including the loss of DLEU7 and miR15a/16–1. When
comparing the gene expression pattern of the cell line with LCLs
derived from normal B lymphocytes, we could single out two
genes, LHX2 and LILRA4 which could have significance for the
development of the CLL condition. LHX2 is expressed in self-
replenishing hematopoietic stem cells, and LILRA4 is involved
in early B cell development. LHX2 expression was not detected
in ex vivo blood CLL cells, however it could be turned on in
dividing CLL precursors and silenced in resting cells. The CLL
derived HG3 LCL is the first cell line that resembles human
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B1 cells both with regard to its surface marker profile
(CD5
+CD20
+CD27
+CD43
+) and its function i.e. spontaneous
natural Ab-secretion.
Materials and Methods
Cell culture. Peripheral blood mononuclear cells (PBMC) were
collected from venous blood of a 70 y old male CLL patient
(Rai stage II) upon informed consent according to the Ethical
committee of Karolinska University Hospital guidelines. The
white blood cell count was 184.1  10
9/l. The lymphocytes
were isolated by Ficoll-Paque (Pharmacia, Uppsala, Sweden).
Sixty-four percent of the cells were B lymphocytes, all were
monoclonal for IgM, l-light chains, CD5
+, CD23
+, FMC7
+,
CD22
+, CD52
+, CD38
+. Twenty percent of the PBMCs were
T cells, 3% were NK cells and the CD4/CD8 ratio was 0.3.
T cells and macrophages were removed as described.
17 CLL cell
(CD5
+/CD19
+) purity in the CD3-depleted populations was
more than 98% and the cells expressed the EBV receptor CD21.
The CLL cells were exposed to the B95–8 EBV strain for 1 h,
washed and then cultured with CD40L human L-cell fibroblasts
in RPMI 1640 medium supplemented with 10% FCS, 100 U/ml
penicillin and 100 mg/ml streptomycin.
17 Cells were frozen
and stored in liquid nitrogen. EBV-infected cell lines were
initiated on several occasions. The efficiency of the infection
was indicated by the expression of the EBV encoded nuclear
protein 2 (EBNA-2) in 20–30% of the cells in 4 d old cultures,
as detected by immunofluorescence staining. The LCLs derived
from normal B cells (LCL-3M, IARC-171), or from CLL cells:
CI,
57-59 MEC1,
60 I83-E95
15 and 232B4
15 were cultured in RPMI
1640 medium supplemented with 10% FCS, 100 U/ml penicillin
and 100 mg/ml streptomycin.
Phenotype analysis of the CLL LCL. Flow cytometry analysis
was performed with mAbs against CD5, CD14, CD19, CD20,
CD23 (Dako); CD27, CD43 (BioLegend); CD31, CD38 (AbD
Serotec); CD69, CD70 (BD Biosciences PharMingen). These
were detected with FITC-, or Cy-ChromeTM -conjugated anti-
mouse IgG (Dako). The cells were washed once with PBS/1%
FCS, incubated for 30 min at 4°C with indicated Abs, washed
once with PBS/1% FCS and resuspended in 500 ml PBS/1%
formaldehyde. Ten thousand events were collected in a FACScan
flow cytometer, and the results were analyzed using CellQuest
software (BD Biosciences).
Immunofluorescence staining. The cells were deposited on
glass slides in a cytospin centrifuge and fixed in acetone-methanol
(2:1). For single staining, following rehydration in balanced salt
solution (BSS), the slides were incubated with primary Ab at
room temperature for 60 min. For EBNA-2, mouse mAb PE2
(IgG1, Leica Biosystem NovoCastra Ltd., dilution 1:50) and for
LMP-1, S-12 (IgG2a, culture supernatant, dilution 1:50) were
used. Following washing in BSS, fluorochrome labeled anti-
mouse Ab was added and the slides were incubated for 30 min
at room temperature for visualization. EBNA-2 was visualized
with goat anti-mouse IgG1-Alexa Fluor 488 (Invitrogen, dilution
1:200) and LMP-1 was detected with goat anti-mouse IgG2a-
Alexa Fluor 594 (Invitrogen, dilution 1:200). The slides were
mounted with Vectashield containing DAPI (Vector Laboratories,
Inc.). For double staining, first EBNA-2 was stained as described
above. Thereafter the slides were washed and the reagents for
detection of LMP-1 were applied. Images were generated with a
Leitz DM RB microscope (Leica Microsystems) using a 100x/
1.32 N.A. oil immersion objective lens. Images were captured
with a Hamamatsu dual-mode cooled charged-coupled-device
camera (C48880) and Hipic 6.4.0 software (Hamamatsu
Photonics) as 8-bit uncompressed TIFF files. Pictures are edited
for optimal color contrast by using Photoshop CS3 (Adobe systems).
G-banding and FISH analysis. G-banding of chromosomes
and FISH was performed by standardized routine methods as
described elsewhere.
61 The probes for FISH analysis were the
following: p53(17p), ATM(11q), D13S1319(13q14.3), LAMP1
(13q34) and CEP12(trisomy 12).
Microarray experiments and data analysis. Microarray pro-
duction was performed as described by Takahashi et al.
62 with
slight modifications. Briefly, 21,632 cDNA clones were PCR
amplified directly from bacterial stocks purchased from Research
Genetics. After ethanol precipitation and transfer to 384-well
plates, clones were printed onto poly-L-lysine coated glass slides.
Two micrograms of poly(A)
+ RNA from HG3 cells and 2 mgo f
poly(A)
+ RNA from each of the two LCLs derived from normal
B cells, IARC-171 and LCL-3M, were reverse transcribed with
oligo(dT) primer and Superscript II (Life Technologies) in the
presence of Cy5-dCTP and Cy3-dCTP (Amersham Pharmacia
Biotech), respectively. The Cy3- and Cy5-labeled cDNA probes
were hybridized to prewarmed (42°C) slides for 20 h at 42°C.
After hybridization, slides were washed, dried and scanned
immediately in a confocal fluorescent scanner. Images were
analyzed by using the software Genepix Pro 3.0 (Axon Instru-
ments). The ratios of net fluorescence from the Cy5-specific
channel to the net fluorescence from the Cy3-specific channel
were calculated for each spot, representing CLL-LCL mRNA
expression relative to the LCLs derived from normal B cells.
Ratios were log-transformed (base 2) and normalized so that the
average log-transformed ratio equaled zero.
SNP-array. High density SNP array on high quality DNA
prepared from HG3 and peripheral blood sample from the HG
patient was performed according to standard protocols for
Affymetrix GeneChip
1 250 K arrays (Affymetrix, Inc.). Briefly,
total genomic DNA was digested with a restriction enzyme
(Nsp1), ligated to an appropriate adaptor for the enzyme, and
subjected to PCR amplification using a single primer. After
digestion with DNase I, the PCR products were labeled with a
biotinylated nucleotide analog using terminal deoxynucleotidyl
transferase and hybridized to the microarray. Hybridized probes
were captured by streptavidin-phycoerythrin conjugates. Copy
number normalization, to produce log(2) ratios, was performed
using the Copy Number Analysis Tool (CNAT) 4.0.1. The
reference set was 82 normal samples analyzed at the Uppsala
Array Platform. Subsequent copy number analysis and group
comparisons were performed using the software BioDiscovery
Nexus Copy Number 3.0 and its built in Rank Segmentation
algorithm, segmenting each interval and estimating copy
numbers.
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PCR amplification of IGHV and IGLV/KV rearrangements.
DNA was isolated as described above. IGHV and IGLV/KV
subgroup-specific PCR amplification was performed using con-
sensus primers, as previously described.
64 The sequence reactions
were performed using either the BigDye Terminator Cycle
Sequencing Reaction kit (Applied Biosystems) or the DYEnamic
ET Dye Terminator Kit (Amersham Biosciences) and analyzed
with an automated DNA sequencer (ABI 377 or ABI3700,
Applied Biosystems; and MegaBACE 500 DNA Analysis System,
Amersham Biosciences). The sequences were aligned to IG
sequences in the IMGT database. IGHV sequences with less than
98% identity to germline were defined as mutated.
Reverse transcription-PCR and RQ-PCR. The cells were
thawed, washed in PBS and total RNA extracted utilizing the
RNeasy Mini Kit (Qiagen, Hilden, Germany). cDNA synthesis
was performed with 1–2 mg of total RNA in a 20 ml reaction
mixture with the High-Capacity cDNA Reverse Transcription kit
(Applied Biosystems). RT-PCR: Separation and visualization of
the PCR products was performed according to standard protocols.
RQ-PCR was performed using the TaqMan Fast Universal PCR
Master Mix and the TaqMan Gene expression assay (Applied
Biosystems): The primers and probes for LHX2, LILRA4,
PARD3, FCRLA and GAPDH (Hs99999905_m1) used as an
internal control, were designed and quality controlled by Applied
Biosystems. All reactions were performed in triplicates twice on
a 7500 Fast Real-Time PCR system (Applied Biosystems). miR
RQ-PCR: RNA was extracted using Trizol solution (Invitrogen)
and 10 ng of total RNA was used for the expression analysis
of miR-15a (assay ID 00389) and miR16–1 (assay ID 00391)
according to manufacturer’s protocol (Applied Biosystems).
RNU6B (assay ID 001093) was used as an internal control.
Chemiluminescent ELISA for oxLDL Abs. CLL mAb binding
to oxLDL was determined in chemiluminescent ELISA according
to previously described methods.
65 The most frequently used
model of oxLDL, malonedialdehyde LDL (MDA-LDL) was
used. Abs against native LDL (nLDL), was also tested. Com-
petition ELISA was performed for the oxLDL-reactive CLL mAb
clones. B/B0 indicates the ratio between bound (cpm) and bound
(cpm) without competitor.
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